6/30/2011
PT ENSEVAL PUTERA MEGATRADING TBK
COMPANY UPDATE
Unaudited YTD 31 March 2011 Results
Passion For Excellence
Table of Contents
I. Enseval In Brief
II. Business Overview
III. Operational Highlights
IV. Financial Highlights
1
6/30/2011
I. Enseval In Brief
Milestones
1973
1973:
PT Enseval
established
in Oct 1973
1993
1994
2003
2007
1994: The
1993 :Trading &
2003: Incorporation
Company
distribution activities
of Subsidiary
transferred to subsidiary, was listed on PT Milenia Dharma
Indonesian StockInsani
Arya Gupta Cempaka,
Exchange
later known as PT EPM
2008
2007: Incorporation of
Subsidiaries PT Enseval
Medika Prima & PT Global
Chemindo Megatrading
2008: Incorporation of
Subsidiaries PT Renalmed
Tiara Utama
Sustainable Growth
Net Sales
Laba (Rugi) Bersih
12,000
350
10,000
300
8,000
250
6,000
200
4,000
150
100
2,000
50
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
-
(50)
(100)
* Figure in IDR Billion
2
6/30/2011
Enseval In Brief
Market Leading Position
in Indonesia
• Largest Pharmaceutical distribution company in Indonesia with 42 full-service
branches, 2 Regional Distribution Company and 23 branches under subsidiary
& employs more than 5.000 employees
Strong Product Portfolio
& Diversification
• Distributes more than 10 well known OTC products, nutrition products, infant
milk, energy drinks and Ethical Products
• Public listed company with professional management that ensure fairness
treatment to all Principals & all stakeholders
Good Corporate
Governance
Strong Financial Track
Record
Enseval’s Commitment
Towards Improvement
• Strong Net Sales growth with CAGR 12.6% from year 2005-2009
• Robust balance sheet figures
• Committed for continuous improvement (ISO 9001:2008, GDP & OHSAS)
• Commitment to always increase market coverage and to invest and own
directly all its assets, land, building, IT infrastructure, and transportation
armada to serve better
Shareholding Structure
PT Tri Sapta Jaya
99.99%
PT Milenia
Dharma Insani
0.5%
99.5%
Kalbe
84.13%
PT Enseval Putera
Megatrading
Tbk
Public
16.25%
PT Enseval
Medika Prima
0.1%
99.90%
PT Global Chemindo
Megatrading
0.1%
99.90%
PT Renalmed Tiara
Utama
98.75%
3
6/30/2011
II. Business Overview
Distribution & Logistic
Largest pharmaceutical distributor In Indonesia
Product Range : Ethical, OTC, Consumer Products, Medical Device &
Raw Material
Our service :
• Warehousing
• Inventory Management
• Freight & Transportation
• Sales & Support
• Order-taking, Billing & Collection
4
6/30/2011
Distribution & Logistic
• Covers more than 150.000 outlets throughout Indonesia
• Cover most pharmacies & hospital
• Cover 80% of consumer & health market
• 24 hour order fulfillment & 4-5 hour order fulfillment for prescription
medicines
• 24 hour service for life saving drugs
• Offers value added services to customers
Medical Device
Offers Distributions & Marketing Services for Medical Devices
•
Product Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry
•
The Company offers Marketing services for medical devices through its
subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in
collaboration with clinics and hospitals through PT Renalmed Tiara Utama.
•
The Company has retained the trust & maintained good relationships with
multi-national principals
5
6/30/2011
Raw
RawMaterial
Material
Leading in Pharmaceutical Raw Materials Market
• Related to : Pharmaceutical Product, Food,
Cosmetics & Veterinary
•
PT Global Chemindo Megatrading offers
trading & marketing of raw material and has
extensive network and collaboration with
Multinational Companies from different
countries, such as : United States, Europe,
China, Japan, Korea and other countries.
Healthcare Services
New Retail Health Service : Mitrasana Clinic
•
Healthcare Services,with facilities such as: Clinic,
Pharmacy, Laboratory & Mini market
•
Until 31 Maret 2011, The Company has 25 Clinics
in Jakarta and its greater areas
•
Offered in 2 business models : direct investment &
collaboration / joint operation models
6
6/30/2011
III. Operational Highlights
Branches
The largest pharmaceutical distribution network throughout the Indonesian
Archipelago, with total 65 branches.
7
6/30/2011
Events Highlight in 2011
•
The Company conducted Extraordinary General Meetings of Shareholders on
March 2nd 2011 for approval on Rights Issue I.
•
The Company completed a Rights Issue I to shareholders in issuing
Preemptive Rights amounting to 428,640,000 shares with a par value of Rp 50
per share, with total amount of IDR 300 Bn to finance 2 years expansion
plan.
Operational Highlight in 2011
•
Infrastructures & Branches Development in branches
• Some initiatives for service quality improvement:
- Enseval Customer Care (ECC) Implementation
- Subdistributor Appointment to expand distribution coverage
throughout Indonesia
- 24 hours Call Center Implementation, ‘After Sales Service’ &
‘Customer Service Online’ in PT Enseval Medika Prima, The
Company’s Subsidiary
• Upgrading Oracle system to Oracle E-Business Suite Release 12 to
futher improved IT capabilities .
• The Company Subsidiary, PT Enseval Medika Prima & PT Global
Chemindo Megatrading have been known in Medical Devices & raw
material market in Indonesia & gained trust from Multinational
Principals
8
6/30/2011
Expansion Plans
2 Years Expansion Plans
• Upgrade existing branches and expand
warehouse capacity to improve service
quality
• Expand distribution coverage to new areas
•Establish several RDC throughout Indonesia
to ensure smooth logistics.
•Upgrade Information and technology
Human Resources
•
Employs over 5,000 personnel with over 2,000 personnel are working in sales and
distribution
•
The Company continues to provide training for all employees to improved its human
resources competencies
•
In year 2011, The Company continues to promote CONIM Program (Continuos
Improvement) to all staffs, both in Headquarters & in all Branches.
9
6/30/2011
Major Principals
Principals Based on Categories
Ethical
OTC
Consumers Product
Major Principals
Principals Based on Categories
Medical Devices & Diagnostic
Raw Material
Friesland Foods Domo
10
6/30/2011
Infrastructures
More than 580
Transportation
Fleet
More than 120
Motorcycles
More than
64.000 Pallets
Size
The Usage of
Oracle System
as IT Platform
IV. Financial Highlights
11
6/30/2011
Financial Highlights
Until YTD 31 March 2011, The Company recorded Net Sales of IDR 2.3 trillion, 12.3%
growth YoY, with Operating Income amounting to IDR 59,5 million
Net Sales (IDR Trillion)
12
10
Operating Income (IDR Billion)
17% 600
16,1%
16%
6,9
8
6
500
5%
15%
3,7%
14%
6,4
2.3
11% 100
0
10%
2009
2010
Net Sales
Q1 2010
3.2%
3%
2%
12% 200
2
2008
4%
3.7%
361
307
13%
4
2.0
363
300
12.3%
13,6%
484
4,9%
4,8%
400
8,6
7,4
2007
6%
5,7%
15,7%
15,4%
75
72
Q1 2010
Q1 2011
1%
0
0%
Q1 2011
2007
2008
2009
Growth (%)
OP
2010
OP Margin
Financial Highlights
Until YTD 31 March 2011, The Company Net Income reached IDR 59.5 million with
Net Income Per Share of IDR 26
Net Income (IDR Billion)
350
3.6%
300
250
200
Net Income Per Share
3.9%
2.6%
3.6%
267
2.6%
329
2.6%
231
257
150
52
100
60
50
0
2007
2008
2009
2010
Q1 2010 Q1 2011
4.5%
4.0%
3.5%
3.0%
2.5%
2.0%
1.5%
1.0%
0.5%
0.0%
160
144
140
120
117
100
80
60
40
23
26
20
0
2007
Net Income (IDR Million)
113
102
2008
2009
2010
Q1 2010
Q1 2011
Net Profit Margin
Net Income Per Share (IDR)
12
6/30/2011
Sales Growth
Net Sales (In IDR Billion )
12.3%
2,282
2,033
16.2%
11.9%
19.7%
882
759
673
753
8.6%
152
Consumer
Products
Ethical
OTC
139
Raw Material
YTD 31 March 2010
15%
10.9%
417
348
94
83
Medical Device
7
Others
9
Consolidation
YTD 31 March 2011
Sales Contribution
Medical DeviceOthers
0%
Raw Material 4%
6%
OTC
18%
Consumer
Products
38%
Unaudited
YTD 31 Mar 2011
Ethical
33%
13
6/30/2011
Assets
Assets
15.7%
3,696
12.0%
3,194
3,141
2,806
42.9%
388
Current Assets
555
Non Current Assets
31 March 2010
Total Assets
31 March 2011
Figure in IDR Billion
Liabilities & Equity
0.2%
1,537 1,537
1,504 1,501
30.3%
2,158
1,656
9.0%
33
Current Liablities
31 March 2010
36
Non Current Liabilities
31 March 2011
Equity
Total Liabilities
31 March 2010
31 March 2010
14
6/30/2011
Thank You
For further information, please contact :
PT Enseval Putera Megatrading Tbk.
Enseval Building, Kawasan Industri Pulogadung
Jalan Pulolentut No.10
Jakarta 13920 ) Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : investor.relations@enseval.com
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading
Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to contain all of the
information that may be material to an investor’s decision. It should be noted that the information
contained in this Presentation is subjected to further review, and that such information may be updated
and/or amended from time to time as circumstances change or more information becomes available.
Some of those revisions or changes may be material.
Each recipient of this Presentation should therefore perform their own independent analysis of the
business, operations, financial condition, creditworthiness, status and affairs of Enseval. Each recipient
should also conduct their own enquiries into the adequacy, accuracy, and completeness of any
information relating to Enseval, as the information and data contained in this Presentation are not
substitutes for the recipient’s independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.
15
6/30/2011
PT ENSEVAL PUTERA MEGATRADING TBK
COMPANY UPDATE
Unaudited YTD 31 March 2011 Results
Passion For Excellence
Table of Contents
I. Enseval In Brief
II. Business Overview
III. Operational Highlights
IV. Financial Highlights
1
6/30/2011
I. Enseval In Brief
Milestones
1973
1973:
PT Enseval
established
in Oct 1973
1993
1994
2003
2007
1994: The
1993 :Trading &
2003: Incorporation
Company
distribution activities
of Subsidiary
transferred to subsidiary, was listed on PT Milenia Dharma
Indonesian StockInsani
Arya Gupta Cempaka,
Exchange
later known as PT EPM
2008
2007: Incorporation of
Subsidiaries PT Enseval
Medika Prima & PT Global
Chemindo Megatrading
2008: Incorporation of
Subsidiaries PT Renalmed
Tiara Utama
Sustainable Growth
Net Sales
Laba (Rugi) Bersih
12,000
350
10,000
300
8,000
250
6,000
200
4,000
150
100
2,000
50
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
-
(50)
(100)
* Figure in IDR Billion
2
6/30/2011
Enseval In Brief
Market Leading Position
in Indonesia
• Largest Pharmaceutical distribution company in Indonesia with 42 full-service
branches, 2 Regional Distribution Company and 23 branches under subsidiary
& employs more than 5.000 employees
Strong Product Portfolio
& Diversification
• Distributes more than 10 well known OTC products, nutrition products, infant
milk, energy drinks and Ethical Products
• Public listed company with professional management that ensure fairness
treatment to all Principals & all stakeholders
Good Corporate
Governance
Strong Financial Track
Record
Enseval’s Commitment
Towards Improvement
• Strong Net Sales growth with CAGR 12.8% from year 2005-2010
• Robust balance sheet figures
• Committed for continuous improvement (ISO 9001:2008, GDP & OHSAS)
• Commitment to always increase market coverage and to invest and own
directly all its assets, land, building, IT infrastructure, and transportation
armada to serve better
Shareholding Structure
PT Tri Sapta Jaya
99.99%
PT Milenia
Dharma Insani
0.5%
99.5%
Kalbe
84.13%
PT Enseval Putera
Megatrading
Tbk
Public
16.25%
PT Enseval
Medika Prima
0.1%
99.90%
PT Global Chemindo
Megatrading
0.1%
99.90%
PT Renalmed Tiara
Utama
98.75%
3
6/30/2011
II. Business Overview
Distribution & Logistic
Largest pharmaceutical distributor In Indonesia
Product Range : Ethical, OTC, Consumer Products, Medical Device &
Raw Material
Our service :
• Warehousing
• Inventory Management
• Freight & Transportation
• Sales & Support
• Order-taking, Billing & Collection
4
6/30/2011
Distribution & Logistic
• Covers more than 150.000 outlets throughout Indonesia
• Cover most pharmacies & hospital
• Cover 80% of consumer & health market
• 24 hour order fulfillment & 4-5 hour order fulfillment for prescription
medicines
• 24 hour service for life saving drugs
• Offers value added services to customers
Medical Device
Offers Distributions & Marketing Services for Medical Devices
•
Product Range : Consumables, Instruments, Laboratories & Diagnostics, and
Products related to Laboratories Industry
•
The Company offers Marketing services for medical devices through its
subsidiary, PT Enseval Medika Prima and Hemodialysis Treatment in
collaboration with clinics and hospitals through PT Renalmed Tiara Utama.
•
The Company has retained the trust & maintained good relationships with
multi-national principals
5
6/30/2011
Raw
RawMaterial
Material
Leading in Pharmaceutical Raw Materials Market
• Related to : Pharmaceutical Product, Food,
Cosmetics & Veterinary
•
PT Global Chemindo Megatrading offers
trading & marketing of raw material and has
extensive network and collaboration with
Multinational Companies from different
countries, such as : United States, Europe,
China, Japan, Korea and other countries.
Healthcare Services
New Retail Health Service : Mitrasana Clinic
•
Healthcare Services,with facilities such as: Clinic,
Pharmacy, Laboratory & Mini market
•
Until 31 Maret 2011, The Company has 25 Clinics
in Jakarta and its greater areas
•
Offered in 2 business models : direct investment &
collaboration / joint operation models
6
6/30/2011
III. Operational Highlights
Branches
The largest pharmaceutical distribution network throughout the Indonesian
Archipelago, with total 65 branches.
7
6/30/2011
Events Highlight in 2011
•
The Company conducted Extraordinary General Meetings of Shareholders on
March 2nd 2011 for approval on Rights Issue I.
•
The Company completed a Rights Issue I to shareholders in issuing
Preemptive Rights amounting to 428,640,000 shares with a par value of Rp 50
per share, with total amount of IDR 300 Bn to finance 2 years expansion
plan.
Operational Highlight in 2011
•
Infrastructures & Branches Development in branches
• Some initiatives for service quality improvement:
- Enseval Customer Care (ECC) Implementation
- Subdistributor Appointment to expand distribution coverage
throughout Indonesia
- 24 hours Call Center Implementation, ‘After Sales Service’ &
‘Customer Service Online’ in PT Enseval Medika Prima, The
Company’s Subsidiary
• Upgrading Oracle system to Oracle E-Business Suite Release 12 to
futher improved IT capabilities .
• The Company Subsidiary, PT Enseval Medika Prima & PT Global
Chemindo Megatrading have been known in Medical Devices & raw
material market in Indonesia & gained trust from Multinational
Principals
8
6/30/2011
Expansion Plans
2 Years Expansion Plans
• Upgrade existing branches and expand
warehouse capacity to improve service
quality
• Expand distribution coverage to new areas
•Establish several RDC throughout Indonesia
to ensure smooth logistics.
•Upgrade Information and technology
Human Resources
•
Employs over 5,000 personnel with over 2,000 personnel are working in sales and
distribution
•
The Company continues to provide training for all employees to improved its human
resources competencies
•
In year 2011, The Company continues to promote CONIM Program (Continuos
Improvement) to all staffs, both in Headquarters & in all Branches.
9
6/30/2011
Major Principals
Principals Based on Categories
Ethical
OTC
Consumers Product
Major Principals
Principals Based on Categories
Medical Devices & Diagnostic
Raw Material
Friesland Foods Domo
10
6/30/2011
Infrastructures
More than 580
Transportation
Fleet
More than 120
Motorcycles
More than
64.000 Pallets
Size
The Usage of
Oracle System
as IT Platform
IV. Financial Highlights
11
6/30/2011
Financial Highlights
Until YTD 31 March 2011, The Company recorded Net Sales of IDR 2.3 trillion, 12.3%
growth YoY, with Operating Income amounting to IDR 59,5 million
Net Sales (IDR Trillion)
12
10
Operating Income (IDR Billion)
17% 600
16,1%
16%
6,9
8
6
500
5%
15%
3,7%
14%
6,4
2.3
11% 100
0
10%
2009
2010
Net Sales
Q1 2010
3.2%
3%
2%
12% 200
2
2008
4%
3.7%
361
307
13%
4
2.0
363
300
12.3%
13,6%
484
4,9%
4,8%
400
8,6
7,4
2007
6%
5,7%
15,7%
15,4%
75
72
Q1 2010
Q1 2011
1%
0
0%
Q1 2011
2007
2008
2009
Growth (%)
OP
2010
OP Margin
Financial Highlights
Until YTD 31 March 2011, The Company Net Income reached IDR 59.5 million with
Net Income Per Share of IDR 26
Net Income (IDR Billion)
350
3.6%
300
250
200
Net Income Per Share
3.9%
2.6%
3.6%
267
2.6%
329
2.6%
231
257
150
52
100
60
50
0
2007
2008
2009
2010
Q1 2010 Q1 2011
4.5%
4.0%
3.5%
3.0%
2.5%
2.0%
1.5%
1.0%
0.5%
0.0%
160
144
140
120
117
100
80
60
40
23
26
20
0
2007
Net Income (IDR Million)
113
102
2008
2009
2010
Q1 2010
Q1 2011
Net Profit Margin
Net Income Per Share (IDR)
12
6/30/2011
Sales Growth
Net Sales (In IDR Billion )
12.3%
2,282
2,033
16.2%
11.9%
19.7%
882
759
673
753
8.6%
152
Consumer
Products
Ethical
OTC
139
Raw Material
YTD 31 March 2010
15%
10.9%
417
348
94
83
Medical Device
7
Others
9
Consolidation
YTD 31 March 2011
Sales Contribution
Medical DeviceOthers
0%
Raw Material 4%
6%
OTC
18%
Consumer
Products
38%
Unaudited
YTD 31 Mar 2011
Ethical
33%
13
6/30/2011
Assets
Assets
15.7%
3,696
12.0%
3,194
3,141
2,806
42.9%
388
Current Assets
555
Non Current Assets
31 March 2010
Total Assets
31 March 2011
Figure in IDR Billion
Liabilities & Equity
0.2%
1,537 1,537
1,504 1,501
30.3%
2,158
1,656
9.0%
33
Current Liablities
31 March 2010
36
Non Current Liabilities
31 March 2011
Equity
Total Liabilities
31 March 2010
31 March 2010
14
6/30/2011
Thank You
For further information, please contact :
PT Enseval Putera Megatrading Tbk.
Enseval Building, Kawasan Industri Pulogadung
Jalan Pulolentut No.10
Jakarta 13920 ) Indonesia
Phone : 62-21-46822422 Fax : 62-21-4609039
Website : www.enseval.com
Email : investor.relations@enseval.com
IMPORTANT NOTICE
This presentation has been prepared for informational purposes only by PT Enseval Putera Megatrading
Tbk. (“Enseval” or the “Company”).
The information contained in this Presentation does not purport to be all-inclusive or to contain all of the
information that may be material to an investor’s decision. It should be noted that the information
contained in this Presentation is subjected to further review, and that such information may be updated
and/or amended from time to time as circumstances change or more information becomes available.
Some of those revisions or changes may be material.
Each recipient of this Presentation should therefore perform their own independent analysis of the
business, operations, financial condition, creditworthiness, status and affairs of Enseval. Each recipient
should also conduct their own enquiries into the adequacy, accuracy, and completeness of any
information relating to Enseval, as the information and data contained in this Presentation are not
substitutes for the recipient’s independent evaluation and analysis.
This presentation is not an offering document and will be updated regularly as necessary.
15